Case Report

**Blastic Natural Killer-Cell Lymphoma Presenting in the Skin**

**Jeng-Wei Tjiu**<sup>1</sup>*, **Cheng-Hsiang Hsiao**<sup>2</sup>

<sup>1</sup>Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan

<sup>2</sup>Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan

**Abstract**

Blastic natural killer (NK)-cell lymphoma is a clinically aggressive hematologic neoplasm with a high incidence of cutaneous involvement. We report a 19-year-old man who presented with asymptomatic, erythematous, infiltrated bean plaques and nodules of various sizes, scattered over the face, trunk and extremities. A skin biopsy specimen revealed diffuse dermal infiltration of medium-sized pleomorphic cells with a blastic appearance. Immunohistochemical studies showed that the tumor cells were positive for CD56, CD43, CD123, and terminal deoxynucleotidyl transferase (TdT). The neoplastic cells were negative for B-cell, T-cell, and myeloid cell markers. In situ hybridization for Epstein-Barr virus encoded RNA (EBER) gave a negative result. Flow cytometric analysis of bone marrow aspirate demonstrated a CD56 positive population of blastic cells. A diagnosis of blastic NK-cell lymphoma was made and the skin lesions regressed after treatment with L-asparaginase-based chemotherapy (L-asparaginase, cyclophosphamide, etoposide). The skin lesions regressed after two sessions of chemotherapy. *(Tzu Chi Med J 2007;19(3):173–178)*

---

**1. Introduction**

Blastic NK-cell lymphoma is an aggressive malignancy and often has cutaneous lesions at initial manifestation. About half of patients have nodal or bone marrow involvement at presentation [1–3]. Most patients with only skin involvement at the beginning rapidly develop bone marrow, peripheral blood, and lymph node involvement. Histologically, blastic NK-cell lymphoma shows monocytic infiltrates of medium sized cells resembling lymphoblasts or myeloblasts with CD56 immunoreactivity [1,4–6]. There are about 150 well-documented cases of blastic NK-cell lymphoma in the literature with several large series representing more than half of published cases [2,6–8]. Suzuki et al reported 47 patients with blastic NK-cell lymphoma collected from a nationwide survey in a Japanese NK-cell tumor study group from 1994–1998 [8]. Petrella et al showed a series of 30 cases from a French study group on cutaneous lymphoma [6]. Bekkenk et al from...
the Netherlands reported an analysis of 11 new cases and reviewed 52 cases from the literature [2]. Massone et al from Austria reported 12 cases of blastic NK-cell lymphoma in their series [7]. Blastic NK-cell lymphoma represented 0.7% of the primary cutaneous lymphoma registered by the French Study Group on Cutaneous Lymphomas [6]. Due to the rarity of this entity, we herein report a case of blastic NK-cell lymphoma.

2. Case report

A 19-year-old man presented with many erythematous nodules and plaques on the face, trunk and extremities. The nodules and plaques developed rapidly over 1 month. The patient did not complain of any systemic symptoms. Physical examination did not reveal any abnormality. Dermatological examination showed many bean-sized infiltrative, erythematous, non-tender nodules or plaques located on the face, neck, trunk, and extremities (Fig. 1). A skin biopsy specimen taken from the back showed infiltration of medium-sized blastic cells in the dermis and subcutis. Monocytic infiltrates of medium-sized blasts made a diagnosis of large tumor cells (i.e. diffuse large B-cell lymphoma) or predominantly small cells (i.e. small lymphocytic lymphoma) unlikely in this case. The neoplastic cells were characterized by dispersed nuclear chromatin, somewhat irregular nuclear membrane and scant cytoplasm (Fig. 2). No epidermotropism, angiodestruction, or angiocentric pattern was found. Immunohistochemical studies showed that the tumor cells were positive for CD56, CD123, CD43, and terminal deoxynucleotidyl transferase (TdT). The tumor cells were negative for CD3, CD20, CD30, CD79a, and myeloperoxidase. In situ hybridization did not detect Epstein-Barr virus encoded RNA (EBER). A bone marrow biopsy showed hypocellular marrow with an M/E ratio of 3:2. Aggregation of blasts was easily demonstrated in bone marrow sections. The blasts had a pleomorphic appearance from myeloblasts or lymphoblasts. Neoplastic cells were positive for CD56 and CD123 (Fig. 3). Flow cytometric analysis found predominantly CD56 positive blasts in the bone marrow. Laboratory investigations, including complete cell counts, liver enzymes, kidney function and electrolyte levels, were all within normal limits. A whole body computed tomography (CT) scan also found no abnormalities. The patient was diagnosed with blastic NK-cell lymphoma with bone marrow involvement and underwent L-asparaginase-based chemotherapy (L-asparaginase, 10,000IU [6000IU/m²] subcutaneous on days 1–7; cyclophosphamide, 600 mg intravenous infusion for 1 hour on day 1–2; etoposide [VP16], 100 mg intravenous infusion on days 1–4). The skin lesions cleared after the first course. However, elevated liver function test (alanine aminotransferase, 383 U/L; reference, 0–35 U/L) postponed subsequent treatment. After liver function returned to normal, a second course of chemotherapy was delivered 6 weeks after the first course with minor side effects of nausea and vomiting. The duration of follow-up was 2 months. This patient will receive allogeneic or autologous stem cell transplantation.

3. Discussion

The World Health Organization (WHO) classification recognizes the following NK-cell malignancies: aggressive NK-cell leukemia; extranodal NK/T-cell leukemia, nasal type; and blastic NK-cell lymphoma [9]. The origin of the neoplastic cells in blastic NK-cell
Fig. 2 — (A) Diffuse non-epidermotropic infiltration of medium-sized blast cells in the dermis (hematoxylin & eosin [H&E], 40×). (B) The tumor cells have dispersed nuclear chromatin, an irregular nuclear membrane, and scant cytoplasm (H&E, 200×). Tumor cells are positive for: (C) CD56 (100×); (D) CD43 (100×); (E) CD123 (100×); and (F) terminal deoxynucleotidyl transferase (100×).
lymphoma has not yet been ascertained. Based on the blastic cytologic appearance and CD56 expression, an NK-precursor origin was initially suggested (9). Simultaneous expression of stem cell markers and the NK-cell receptor complex CD94/NKG2 also favored origin from an NK-cell precursor (10). But recent studies found evidence suggesting early plasmacytoid type 2 dendritic cell (DC2) origins (11,12).

Clinically, blastic NK-cell lymphoma commonly presents in the skin with solitary or multiple nodules or tumors with or without concurrent extracutaneous localization (4). About half of patients have bone marrow involvement at presentation (2,3,13). The average age at presentation ranged from 53 to 74.3 years in several reported series (2,7,8).

Histologically, blastic NK-cell lymphoma is characterized by an infiltrate of medium-sized neoplastic cells with blastoid morphology. The epidermis is not involved as a rule, whereas involvement of the subcutaneous tissue is common. The neoplastic cells have finely dispersed chromatin, and absent or indistinct nucleoli resembling lymphoblasts or myeloblasts (2,3,13). A special immunophenotypic feature of blastic NK-cell lymphoma is positivity for CD56 antigen. The tumor cells usually also express CD4 and CD43 (8). Expression of CD2, CD7, cytotoxic molecules, TdT, CD34 and CD68 varies. Other T cell markers and myelomonocytic markers are negative (14). Since lymphoblastic and myeloblastic neoplasms can also be positive for CD56, stains for CD3 and myeloperoxidase should always be performed in order to exclude these entities (3). The cells express CD123, which supports a relationship with plasmacytoid dendritic cells (15). Recent studies demonstrated that blastic NK-cell lymphoma expresses markers typical of plasmacytoid dendritic cells, in particular the IL-3R alpha chain (CD123) (15).

The differential diagnosis includes other CD56+ lymphomas with cutaneous involvement (2). These include extranodal NK/T-cell lymphoma, nasal type; CD56+ myeloid leukemia; and cutaneous Cd30+ lymphoproliferation with CD56 expression (2,3). Extranodal NK/T-cell lymphoma is nearly always an EBV+ lymphoma. The skin is the second most common site of involvement after the nasal cavity/nasopharynx (3,9,13). Prominent angiocentricity and
angiodestruction are often accompanied by extensive necrosis. The neoplastic cells of extranodal NK/T-cell lymphoma express CD56, cytoplasmic CD3, and cytotoxic proteins, but lack surface CD3 (2,3). In this case, EBV was not detected by in situ hybridization. Because the tumor cells were negative for EBV, the possibility of extranodal NK/T-cell lymphoma, nasal type, was excluded. NK-cell lymphoma and CD56+ myeloid leukemia have great similarity in clinical, histological and immunohistological presentations (2). However, our case had negative staining for the myeloid marker myeloperoxidase and this excluded the possibility of CD56+ myeloid leukemia.

There is no standard treatment for advanced blastic NK-cell lymphoma (3,13). Initial treatment consists of multiagent chemotherapy in the majority of patients, and most patients receive CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or a CHOP-like regimen (2,8). Response to combination chemotherapy, such as CHOP, is minimal or transient and early progression is common (2,8). Radiation therapy is effective for localized disease only. A CHOP-like regimen and radiotherapy are inadequate therapies for this type of neoplasm. More aggressive therapies directed to allogeneic stem cell transplantation are probably superior. Young patients treated with aggressive regimens used in acute leukemia have a better prognosis than patients treated with CHOP-like regimens (16). Long-term remission of blastic NK/T-cell lymphoma was reported after autologous peripheral blood stem cell transplantation (17). Significant survival benefits were found in patients with blastic NK-cell lymphoma who underwent hematopoietic stem cell transplantation (18). Therefore, allogeneic or autologous stem cell transplantation is a promising treatment strategy and should be recommended to the patient. Rapid clearance of skin lesions represents responsiveness of blastic NK-cell lymphoma to l-asparaginase-based chemotherapy. The rationale is based on reports that l-asparaginase is effective in the treatment of NK/T-cell lymphoma (19–22). Childhood blastic NK-cell leukemia was also reportedly successfully treated with l-asparaginase (23). l-asparaginase could induce selective apoptosis of natural killer-cell tumors (24). Recently, an l-asparaginase-based regimen was reported to be promising new salvage chemotherapy regimen in CHOP failures and improved treatment outcome in midline NK/T-cell lymphoma, nasal type (25).

The prognosis of blastic NK-cell lymphoma is poor, with a median survival of 14 months and 2- and 5-year overall survivals of 33% and 6%, respectively (2). Patients with only skin involvement tend to have longer survival than those with extracutaneous disease (2,8). Young age (<40 years), TdT expression of >50% neoplastic cells, and cutaneous involvement only were independent prognostic variables for a better prognosis (2,8).

In Taiwan, Lin et al reported a 35-year-old man diagnosed with blastic NK-cell lymphoma with skin and bone marrow involvement (26). He initially presented with erythematous and purpuric plaques on the face and trunk. Blastic-like lymphoid cells were found infiltrating the dermis and subcutis in a biopsy specimen. The tumor cells were immunoreactive to CD56 but not other T-cell, B-cell, or myeloid markers or EBV. The patient did not attain remission and skin lesions persisted despite four courses of CHOP. The clinical, histological and immunohistological characteristics of our present case are similar to that reported by Lin et al (26). However, our patient was younger and more responsive to the l-asparaginase-based chemotherapy.

In conclusion, we reported a rare case of blastic NK-cell lymphoma with bone marrow involvement. Accurate pathological diagnosis of this neoplasm is essential for prognosis and treatment. Although the patient responded to initial chemotherapy, hematopoietic stem cell transplantation may be needed to prolong his survival.

References

9. Jaffe ES, Harris NL, Stein H, et al. World Health Organization Classification of Tumors. Pathology and Genetics of


